The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle "excessive autophagy" which is relevant to the therapy resistance
Fukuda, T.
No to Hattatsu 42(2): 114-116
2010
ISSN/ISBN: 0029-0831 PMID: 23858594 Document Number: 643303
Document emailed within 1 workday
Related Documents
Ley-Martos, M.; Salado-Reyes, Mía.J.; Espinosa-Rosso, Rúl.; Solera-García, Jús.; Jiménez-Jiménez, L. 2015: Variability in the clinical presentation of Pompe disease: development following enzyme replacement therapy Revista de Neurologia 61(9): 416-420Morrow, T. 2006: Pompe disease therapy presents coverage challenge Managed Care 15(6): 63-64
Bonnici, F.; Shapiro, R.; Joffe, H.S.; Petersen, E.M. 1980: Angiocardiographic and enzyme studies in a patient with type II glycogenosis (Pompe's disease). A case report South African Medical Journal 58(21): 860-862
Lamabadusuriya, S.P.; Canagarayar, U.T.; Vijeyaratnam, G. 1979: A family with Pompe's disease (glycogenesis type II) Ceylon Medical Journal 24(1-2): 42-44
Aruj, P.K.; Rausch, S.; De Vito, E.L. 2015: Thymic neuroendocrine carcinoma with Pompe's disease of the adult Medicina 75(5): 315-318
Accomando, S.; Montaperto, D.; Fragapane, M.L.; Amato, G.M.; Corsello, G.; Cappello, F.; Maresi, E. 2005: An interesting question of Pompe disease. A case report Minerva Pediatrica 57(6): 423-427
Lin, C.Y.; Hwang, B.; Hsiao, K.J.; Jin, Y.R. 1986: Study of alpha-D-glucosidase activity in patients with Pompe's disease Journal of the Formosan Medical Association 85(8): 766-770
Cottrill, C.M.; Johnson, G.L.; Noonan, J.A. 1987: Parental genetic contribution to mode of presentation in Pompe disease Pediatrics 79(3): 379-381
Kapica-Topczewska, K.; Tarasiuk, J.; Kułakowska, A.; Drozdowski, W.ła. 2008: A case of Pompe disease treated with acid alpha-glucosidase Neurologia i Neurochirurgia Polska 42(4): 353-357
Lin, C.Y.; Shieh, J.J. 1996: Molecular study on the infantile form of Pompe disease in Chinese in Taiwan Zhonghua Minguo Xiao Er Ke Yi Xue Hui Za Zhi Zhonghua Minguo Xiao Er Ke Yi Xue Hui 37(2): 115-121
Nicolino, M. 2007: Clinical development of acid alpha-glucosidase for the treatment of Pompe disease Presse Medicale 36(Special Issue 1): 1s100-1s107
Cornu, F. 1998: Gaucher's disease and enzyme replacement therapy Annales Pharmaceutiques Francaises 56(3): 102-107
Zimran, A.; Elstein, D. 2014: Management of Gaucher disease: enzyme replacement therapy Pediatric Endocrinology Reviews: Per 12(Suppl 1): 82-87
Schiffmann, R. 2006: Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy Acta Neurologica Belgica 106(2): 61-65
Parco, S.; Bruno, G.; Durighello, M.; Giorgini, R.; Simeone, R.; Bembi, B. 1999: Hematologic response in type i Gaucher's disease after enzyme replacement therapy Haematologica 84(4): 376-377
Rosenthal, D.I.; Doppelt, S.H.; Mankin, H.J.; Dambrosia, J.M.; Xavier, R.J.; McKusick, K.A.; Rosen, B.R.; Baker, J.; Niklason, L.T.; Hill, S.C. 1995: Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase Pediatrics 96(4 Pt 1): 629-637
Alberti, C. 2016: Prostate cancer cell both microRNA aberrant expression-mediated autophagy and radiation therapy resistance with short cross-reference to epigenetic/genetic mechanism implications European Review for Medical and Pharmacological Sciences 20(6): 1001-1002
Schneider, M.U.; Knoll-Ruzicka, M.L.; Domschke, S.; Heptner, G.; Domschke, W. 1985: Pancreatic enzyme replacement therapy: comparative effects of conventional and enteric-coated microspheric pancreatin and acid-stable fungal enzyme preparations on steatorrhoea in chronic pancreatitis Hepato-Gastroenterology 32(2): 97-102
Brennan, G.T.; Saif, M.W. 2019: Pancreatic Enzyme Replacement Therapy: a Concise Review Jop: Journal of the Pancreas 20(5): 121-125
Ametov, A.S.; Kochergina, I.I.; Ulanova, K.A. 2010: Effect of insulin therapy on insulin resistance and risk for ischemic heart disease and death from cardiovascular pathology in patients with diabetes mellitus, type 2 Terapevticheskii Arkhiv 82(3): 42-46